Adaptive Biotechnologies Earnings Call Transcripts
Fiscal Year 2026
-
Strong volume growth, guideline inclusions, and pricing improvements are driving double-digit expansion, with EMR integration and clinical data supporting further adoption. International expansion is capital-efficient, and the technology remains the gold standard in MRD, with robust financial margins and a promising immune medicine pipeline.
-
MRD testing volumes and revenues continue to grow, driven by blood-based testing, community expansion, and updated clinical guidelines. ASPs are rising, with a clear path to $1,700–$1,800 by 2029, and the company expects positive adjusted EBITDA and free cash flow in 2026. Immune medicine is advancing through data partnerships and predictive modeling.
Fiscal Year 2025
-
Achieved 55% revenue growth and 68% lower cash burn in 2025, with MRD profitability and strong clonoSEQ test volume growth. 2026 guidance targets 22% MRD revenue growth, over 30% test volume increase, and positive company-wide adjusted EBITDA and free cash flow by year-end.
-
Gross margins improved by 2% in Q3, with a 5%-8% lift expected over the next year. EMR integration and blood-based testing are driving growth, supported by expanded reimbursement and new clinical guidelines. Key catalysts include further data generation, margin gains, and major clinical trial readouts.
-
Strong quarterly growth in volumes, ASP, and gross margin was supported by expanded payer coverage, EMR integration, and robust data generation. Pharma backlog exceeds $200 million, with a shift toward primary endpoints, and R&D investments in AI and autoimmunity are advancing, all while maintaining profitability.
-
Q3 saw robust MRD revenue growth, margin expansion, and positive cash flow, driven by clinical adoption, EMR integration, and payer wins. Full-year MRD guidance was raised, with strong volume and ASP momentum, while regulatory and competitive positioning remain favorable.
-
Achieved key operational and financial milestones ahead of schedule, including EBITDA profitability and major EMR integrations. Community market penetration and blood-based testing are driving rapid growth, while clinical utility data and new guidelines support increased adoption. ASP and margin improvements, along with strategic partnerships, position the business for strong future performance.
-
Q2 saw 36% revenue growth, MRD business profitability, and raised full-year guidance. EMR integrations and updated guidelines are driving volume and pricing gains, with strong momentum in both clinical and pharma MRD segments.
-
Record Q1 performance driven by volume growth, EMR integration, and new indications. Strategic partnerships, operational improvements, and a focus on blood-based testing and community expansion support long-term growth and margin improvement.
-
Q1 delivered 25% revenue growth, record MRD test volumes, and improved gross margin, prompting raised full-year guidance for MRD revenue and lower cash burn. Strategic payer agreements, new assay launches, and accelerating EMR integrations support continued momentum.
-
Strong 2024 results set the stage for continued growth in 2025, driven by pricing gains, EMR integration, and expanding clinical utility. Strategic partnerships and disciplined cost management support margin expansion, with profitability targeted in the second half of 2025.
-
Strong cash position and operational efficiencies are enabling MRD business profitability by 2025 and targeted investment in immune medicine. clonoSEQ’s leadership is reinforced by regulatory wins, new partnerships, and margin expansion initiatives, while the IM business advances digital and antibody programs with disciplined spending.
Fiscal Year 2024
-
MRD revenue grew 42% in 2024, driven by higher test volumes, improved ASP, and expanded payer coverage, while Immune Medicine advanced drug discovery efforts. 2025 guidance targets 24% MRD revenue growth, margin expansion, and Adjusted EBITDA positivity in MRD in H2.
-
Q3 2024 saw 22% revenue growth, driven by a 52% MRD revenue increase and operational efficiencies. Guidance was raised for MRD revenue and lowered for operating spend and cash burn, with strong momentum in pharma and EMR integration.
-
Organizational changes and disciplined resource allocation have driven momentum in MRD and immune medicine. MRD test penetration is growing, especially in community settings, with EMR integrations and clinical evidence supporting adoption. Pharma milestones are rising post-ODAC, and immune medicine R&D is advancing.
-
Q2 saw strong MRD revenue growth, improved margins, and reduced cash burn, prompting raised full-year guidance. Clinical and pharma MRD segments outperformed, with operational efficiencies and EMR integration supporting future growth.
-
MRD business is positioned for strong growth, leveraging its FDA-cleared clonoSEQ assay, robust clinical data, and expanding market access. 2024 revenue is guided at $135M–$140M, with profitability targeted by 2025–2026 and major growth expected from new indications, EMR integration, and regulatory tailwinds.